← Back to Screener
Armata Pharmaceuticals, Inc. Common Stock (ARMP)
Price$7.50
Value ScoreF
Growth ScoreB
Momentum ScoreC
Favorite Metrics
Price vs S&P 500 (26W)-5.61%
Price vs S&P 500 (4W)-9.63%
VGM Score48.38
Market Capitalization$275.33M
All Metrics
Book Value / Share (Quarterly)$0.53
P/TBV (Annual)1.74x
Revenue Growth (3Y)-3.81%
Cash Flow / Share (Quarterly)$-0.67
Price vs S&P 500 (YTD)11.27%
Net Profit Margin (TTM)-5432.80%
EPS (TTM)$-7.76
10-Day Avg Trading Volume0.06M
EPS Excl Extra (TTM)$-7.76
Revenue Growth (5Y)43.00%
EPS (Annual)$-4.80
ROI (Annual)-102.33%
Net Profit Margin (5Y Avg)-1324.46%
Cash / Share (Quarterly)$0.13
Revenue Growth QoQ (YoY)60.69%
ROA (Last FY)-226.06%
Revenue Growth TTM (YoY)10.70%
EBITD / Share (TTM)$-0.98
ROE (5Y Avg)-117.52%
Operating Margin (TTM)-715.65%
Cash Flow / Share (Annual)$-0.72
P/B Ratio14.42x
P/B Ratio (Quarterly)2.16x
Net Income / Employee (Annual)$-2,849,200
EV / Revenue (TTM)117.93x
Net Interest Coverage (TTM)-0.27x
ROA (TTM)-356.62%
EPS Incl Extra (Annual)$-4.80
Current Ratio (Annual)1.19x
Quick Ratio (Quarterly)0.52x
3-Month Avg Trading Volume0.06M
52-Week Price Return282.65%
Revenue / Employee (TTM)$85,300
Tangible BV / Share (Quarterly)$0.24
P/S Ratio (Annual)56.14x
Asset Turnover (Annual)0.06x
52-Week High$16.34
Operating Margin (5Y Avg)-740.17%
EPS Excl Extra (Annual)$-4.80
CapEx CAGR (5Y)-7.95%
Tangible BV CAGR (5Y)56.05%
26-Week Price Return2.32%
Quick Ratio (Annual)1.02x
13-Week Price Return-31.57%
Total Debt / Equity (Annual)0.00x
Current Ratio (Quarterly)0.64x
Enterprise Value$613.48M
Revenue / Share Growth (5Y)22.08%
Asset Turnover (TTM)0.07x
Book Value / Share Growth (5Y)-38.52%
Revenue / Employee (Annual)$80,400
Pretax Margin (Annual)-3544.03%
Cash / Share (Annual)$0.24
3-Month Return Std Dev108.79%
Net Income / Employee (TTM)$-4,633,000
ROE (Last FY)-102.33%
Net Interest Coverage (Annual)-0.15x
EPS Basic Excl Extra (Annual)$-4.80
Receivables Turnover (TTM)4.70x
Total Debt / Equity (Quarterly)1.38x
EPS Incl Extra (TTM)$-7.76
Receivables Turnover (Annual)4.17x
ROI (TTM)-81.23%
P/S Ratio (TTM)52.93x
Pretax Margin (5Y Avg)-1324.46%
Revenue / Share (Annual)$0.14
Tangible BV / Share (Annual)$0.71
Price vs S&P 500 (52W)258.29%
Year-to-Date Return19.43%
5-Day Price Return-3.85%
EPS Normalized (Annual)$-4.80
ROA (5Y Avg)-77.97%
Net Profit Margin (Annual)-3544.03%
Month-to-Date Return-8.20%
Cash Flow / Share (TTM)$-1.62
EBITD / Share (Annual)$-0.97
Operating Margin (Annual)-747.02%
LT Debt / Equity (Annual)0.38x
ROI (5Y Avg)-116.66%
LT Debt / Equity (Quarterly)0.38x
EPS Basic Excl Extra (TTM)$-7.76
P/TBV (Quarterly)4.68x
P/B Ratio (Annual)1.24x
Pretax Margin (TTM)-5432.80%
Book Value / Share (Annual)$1.00
Price vs S&P 500 (13W)-39.82%
Beta1.30x
Revenue / Share (TTM)$0.14
ROE (TTM)-120.00%
52-Week Low$1.74
vGradeF
gGradeB
mGradeC
vgmGradeC
Show chart for
Earnings Surprise History
Q1 26-3.16est. -0.39
Analyst Recommendations
Feb 2026
Mar 2026
Apr 2026
May 2026
4.13
4.13
4.13
4.13
Industry Peers — Biological Products(178)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
ARMPArmata Pharmaceuticals, Inc. Common Stock | F | B | C | $7.50 |
| AMGNAmgen Inc | C | C | C | $349.58 |
| GILDGilead Sciences Inc | C | B | C | $129.16 |
| ARGXargenx SE American Depositary Shares | D | A | B | $891.32 |
| RVMDRevolution Medicines, Inc. Common Stock | F | — | A | $149.23 |
| BIIBBiogen Inc. Common Stock | B | D | B | $195.34 |
| BNTXBioNTech SE American Depositary Share | C | C | D | $88.08 |
| MRNAModerna, Inc. Common Stock | C | B | B | $47.44 |
| NBIXNeurocrine Biosciences Inc | C | B | B | $163.88 |
| EXELExelixis Inc | C | B | B | $52.70 |
| KRYSKrystal Biotech, Inc. Common Stock | D | B | A | $301.00 |
About
Armata Pharmaceuticals develops bacteriophage therapeutics to treat antibiotic-resistant bacterial infections using proprietary phage-based technology. The company has clinical-stage candidates targeting major pathogens including Pseudomonas aeruginosa and Staphylococcus aureus, with additional programs in development. Armata is also collaborating with Merck on synthetic phage candidates for an undisclosed infectious disease target, diversifying its pipeline across difficult-to-treat infections.